相似文献
1
Ustekinumab.
MAbs. 2009 May-Jun;1(3):216-21. doi: 10.4161/mabs.1.3.8593.
2
Ustekinumab for the treatment of psoriatic arthritis.
Expert Rev Clin Immunol. 2014 Feb;10(2):189-202. doi: 10.1586/1744666X.2014.878649.
3
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
Drug Saf. 2019 Jun;42(6):751-768. doi: 10.1007/s40264-019-00797-3.
4
Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
J Drugs Dermatol. 2012 Feb;11(2):160-7.
5
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Drug Des Devel Ther. 2016 Nov 11;10:3685-3698. doi: 10.2147/DDDT.S102141. eCollection 2016.
6
Ustekinumab for psoriasis and psoriatic arthritis.
J Rheumatol Suppl. 2012 Jul;89:86-9. doi: 10.3899/jrheum.120253.
7
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Lancet. 2009 Feb 21;373(9664):633-40. doi: 10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11.
8
New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Am J Clin Dermatol. 2011 Apr 1;12(2):113-25. doi: 10.2165/11538950-000000000-00000.
9
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Ann N Y Acad Sci. 2009 Dec;1182:97-110. doi: 10.1111/j.1749-6632.2009.05070.x.
10
Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Am J Clin Dermatol. 2012 Apr 1;13(2):135-7. doi: 10.2165/11208650-000000000-00000.
引用本文的文献
1
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.
Psoriasis (Auckl). 2025 Apr 11;15:127-144. doi: 10.2147/PTT.S510141. eCollection 2025.
2
Brain interleukins and Alzheimer's disease.
Metab Brain Dis. 2025 Feb 1;40(2):116. doi: 10.1007/s11011-025-01538-5.
3
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease.
J Crohns Colitis. 2025 Jan 11;19(1). doi: 10.1093/ecco-jcc/jjaf006.
4
Roles of Cytokines in Alzheimer's Disease.
Int J Mol Sci. 2024 May 26;25(11):5803. doi: 10.3390/ijms25115803.
5
Biologics and Biosimilars in Psoriasis.
Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23.
6
The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment.
Medicina (Kaunas). 2022 Oct 28;58(11):1552. doi: 10.3390/medicina58111552.
7
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.
Nat Rev Rheumatol. 2020 Jan;16(1):32-52. doi: 10.1038/s41584-019-0337-0. Epub 2019 Dec 12.
8
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012804. doi: 10.1002/14651858.CD012804.pub2.
9
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.
Psoriasis (Auckl). 2018 Nov 13;8:83-92. doi: 10.2147/PTT.S165943. eCollection 2018.
10
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions.
Am J Rhinol Allergy. 2018 Sep;32(5):412-423. doi: 10.1177/1945892418787132. Epub 2018 Jul 19.
本文引用的文献
1
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Expert Rev Neurother. 2009 Mar;9(3):319-21. doi: 10.1586/14737175.9.3.319.
2
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Lancet. 2009 Feb 21;373(9664):633-40. doi: 10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11.
3
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Gastroenterology. 2008 Oct;135(4):1130-41. doi: 10.1053/j.gastro.2008.07.014. Epub 2008 Jul 17.
4
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X.
5
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.
6
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4.
7
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
J Am Acad Dermatol. 2008 May;58(5):851-64. doi: 10.1016/j.jaad.2008.02.040.
8
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
J Am Acad Dermatol. 2008 May;58(5):826-50. doi: 10.1016/j.jaad.2008.02.039.
9
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Arch Dermatol. 2008 Feb;144(2):200-7. doi: 10.1001/archdermatol.2007.63.
10
Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275.
Cell Immunol. 2007 May;247(1):1-11. doi: 10.1016/j.cellimm.2007.06.006. Epub 2007 Aug 29.
Zotero 插件